ionispharma.comEvery Moment Matters | Ionis

Ionis: A force for life Executive & Leadership Team Board of Directors Akcea Therapeutics Corporate Responsibility Diversity Equity & Inclusion DEI Journey Demographics DEI Structure DEI Community Employee Resource Groups Ionis Innovation Technology Pipeline Ionis Neurology + Innovation in Neurology Transforming the Management of Neurologic Diseases RNA-Targeted Regulation of Proteins Delivering RNA-Targeted Medicines + Pipeline Insights and Medicines Transforming the Management of Neurology + Community Connection Ion-ARPA Initiative Grants & Sponsorships Patients Patients Patient Resources Patient Experiences Clinical Trials Expanded Access Policy Medicines Investors & media Overview Newsroom Investors & Media Press Releases Company Statements InBriefs Media Center Stock Information Investors & Media Stock Quote & Chart Analyst Coverage Ownership Profile Financials Investors & Media SEC Filings Annual Reports Governance Back To Main Investors & Media Governance Documents Committee Composition Investor Resources Investors & Media Investor FAQs Settlement Information Contact Us Events Investors & Media Events Eye On Ionis InnovatIONS Podcast Ionis in the News Every Moment Matters Careers Our Culture Working at Ionis Postdoctoral Program Intern Program Follow Us Search for: Every Moment Matters... in the Discovery, Development & Delivery of Life Transforming Genetic Medicines We Work at the Intersection of Innovation and Determination Every milestone we achieve may provide a patient the possibility of reaching another important milestone in their lives. We understand that every one of these moments matter. It’s with this in mind, that we remain steadfast and focused on discovering, developing and delivering medicines that target the root causes of diseases so that these people may continue to plan and look forward to their future. We honor the resilience and resolve of the sick people who depend on us by continuing to push the boundaries of science. Know Our History We Develop Genetic Medicines with Patients as Partners One simple moment can become truly extraordinary, especially when you’re battling a devastating disease. This is why the Ionis team works tirelessly to discover, develop, and deliver potentially life-transforming medicines for the patients who depend on them. We look to patients to better understand what it means to live with a disease, so our genetic medicines can make the most meaningful contribution to improve their lives. Feel Our Inspiration We Are Transforming the Standard of Care and Pioneering New Markets As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and providing hope for patients. Our broadly applicable, versatile, and rapidly advancing technology platform powers our ability to design targeted medicines to treat rare diseases as well as those that affect millions. Review our pipeline We Are a Force For Life Ionis is proud of the moments we share to support and uplift one other, as well as our contributions to support equity, diversity and inclusion in everything we do. If you are driven to deliver on the promise of genetic medicines and want to be a force for life to patients seeking more hopeful futures, come join us. Join our team » Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information click here to read more. Press releases View all press releases » May 7, 2024 Ionis reports first quarter 2024 financial results orange-arrow April 25, 2024 Ionis Publishes 2023 Corporate Responsibility Report orange-arrow April 23, 2024 Ionis to hold first quarter 2024 financial results webcast orange-arrow Ionis: A history of advancing science The Field of Antisense Oligoneucleotides is born – Antisense RNA is first used to inhibit protein production Ionis IPO First proven in vivo antisense activities Chimeric (gapmer) antisense medicines with proven pharmacological advantages demonstrated First Antisense Drug Reaches the Market – Vitravene (fomivirsen) is approved as a treatment for CMV-induced retinitis in immunocompromised patients with AIDS Ionis initiates cardiovascular program Selection of constrained ethyl (cET) as generation 2.5 chemistry, providing enhanced potency and broad distribution to multiple tissues. Akcea, Ionis’ first commercial affiliate, founded Approval of SPINRAZA Approval for TEGSEDI 1978 1989 1991 1992 1993 1995 1998 1999 2000 2003 2010 2013 2014 2015 2016 2017 2018 2019 First Generation Chemistry chosen – Antisense oligonucleotides with phosphorothioate (PS) substitutions are more stable and able to distribute broadly throughout the body, making selected RNase H1 based antisense as a key mechanism Ionis founded by Stanley T. Crooke, M.D., Ph.D. Classification of potential antisense mechanisms 2′-0-methoxyethyl (2’MOE) discovered, making antisense medicines more RNA-like, with greater affinity for targets, greater potency RNase H1 characterized enabling design of optimized antisense therapies Human genome project completed, revolutionizing the diagnosis and treatment of human diseases Ionis initiates neurological disease program Approval of KYNAMRO Demonstrated increased uptake of therapies in the liver by linking a GalNAc molecule to the antisense oligonucleotide Further identification of mechanisms of cell uptake and intracellular distribution Akcea IPO EU approval for WAYLIVRA 1978 1989 1991 1992 1993 1995 1998 1999 2000 2003 2010 2013 2014 2015 2016 2017 2018 2019 1978 The Field of Antisense Oligoneucleotides is born – Antisense RNA is first used to inhibit protein production 1989 First Generation Chemistry chosen – Antisense oligonucleotides with phosphorothioate (PS) substitutions are more stable and able to distribute broadly throughout the body, making selected RNase H1 based antisense as a key mechanism Ionis founded by Stanley T. Crooke, M.D., Ph.D. 1991 Ionis IPO 1992 Classification of potential antisense mechanisms 1993 First proven in vivo antisense activities Chimeric (gapmer) antisense medicines with proven pharmacological advantages demonstrated 1995 2′-0-methoxyethyl (2’MOE) discovered, making antisense medicines more RNA-like, with greater affinity for targets, greater potency 1998 First Antisense Drug Reaches the Market – Vitravene (fomivirsen) is approved as a treatment for CMV-induced retinitis in immunocompromised patients with AIDS 1999 RNase H1 characterized enabling design of optimized antisense therapies 2000 Ionis initiates cardiovascular program 2003 Human genome project completed, revolutionizing the diagnosis and treatment of human diseases Ionis initiates neurological disease program 2010 Selection of constrained ethyl (cET) as generation 2.5 chemistry, providing enhanced potency and broad distribution to multiple tissues. 2013 Approval of KYNAMRO Demonstrated increased uptake of therapies in the liver by linking a GalNAc molecule to the antisense oligonucleotide 2014 Akcea, Ionis’ first commercial affiliate, founded 2015 Further identification of mechanisms of cell uptake and intracellular distribution 2016 Approval of SPINRAZA 2017 Akcea IPO 2018 Approval for TEGSEDI 2019 EU approval for WAYLIVRA latest updates Ionis reports first quarter 2024 financial results Ionis Publishes 2023 Corporate Responsibility Report Ionis to hold first quarter 2024 financial results webcast Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome Ionis to hold olezarsen Phase 3 data webcast Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH ©1989 – 2024 Ionis...